Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Exclusion Criteria

• •1. Unwilling or unable to give written informed assent or consent to participate in the study.
• •2. Perceived to be unreliable or unavailable for the duration of the study period.
• •3. Previous confirmed or suspected disease caused by N. meningitidis.
• •4. Previously immunized with a meningococcal vaccine (licensed or investigational).
• •5. Receipt of any investigational or non-registered product within 30 days prior to enrolment or who expect to receive an investigational drug or vaccine prior to the completion of the study.
• •6. Receipt or plan to receive any vaccines within 30 days before and after administration of each dose of the study vaccine.
• •(certain exceptions influenza vaccines apply)
• •7. Significant acute infection within the 7 days prior to enrolment or body temperature of 38°C or greater within 3 days prior to enrolment.
• •8. Previous serious acute, chronic or progressive disease, epilepsy or any progressive neurological disease or history of Guillain-Barre syndrome.
• •9. History of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components
• •10. Impairment/alteration of immune function, either congenital or acquired or resulting from (for example):
• •* receipt of immunosuppressive therapy,
• •* receipt of immunostimulants,
• •* receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives.
• •11. Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.